Ginkgo Bioworks Holdings (DNA) Net Income towards Common Stockholders (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) reported Net Income towards Common Stockholders of -$6.5 million for Q1 2026, up 14.63% on a YoY basis from -$5.7 million in Q1 2025, and up 91.92% quarter-over-quarter from -$80.8 million in Q4 2025.

Ginkgo Bioworks Holdings (DNA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Ginkgo Bioworks Holdings has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$6.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 14.63% year-over-year to -$6.5 million; the trailing twelve-month figure through Mar 2026 stood at -$228.3 million (up 41.27% YoY), and the FY2025 full-year result was -$312.8 million, up 42.83% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$6.5 million, up from -$80.8 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$6.5 million in Q1 2026, with the low at -$670.6 million in Q2 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$222.4 million across 5 years, with a median of -$173.1 million in 2022.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 1131.22% — and 2025, when it soared 95.39%.
  • Ginkgo Bioworks Holdings' Net Income towards Common Stockholders stood at -$173.1 million in 2022, then fell by 22.31% to -$211.7 million in 2023, then surged by 49.2% to -$107.5 million in 2024, then gained by 24.91% to -$80.8 million in 2025, then surged by 91.92% to -$6.5 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$6.5 million (Q1 2026), -$80.8 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Ginkgo Bioworks Holdings 546.79 Mn 546.79 Mn 16.38 Mn -6.53 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.53 Mn
Dec 31, 2025 -80.75 Mn
Sep 30, 2025 -80.76 Mn
Jun 30, 2025 -60.30 Mn
Mar 31, 2025 -7.65 Mn
Dec 31, 2024 -107.53 Mn
Sep 30, 2024 -56.40 Mn
Jun 30, 2024 -217.18 Mn
Mar 31, 2024 -165.91 Mn
Dec 31, 2023 -211.69 Mn
Sep 30, 2023 -302.89 Mn
Jun 30, 2023 -173.32 Mn
Mar 31, 2023 -204.97 Mn
Dec 31, 2022 -173.08 Mn
Sep 30, 2022 -670.13 Mn
Jun 30, 2022 -670.57 Mn
Mar 31, 2022 -590.51 Mn
Dec 31, 2021 -1.60 Bn
Sep 30, 2021 -102.41 Mn
Jun 30, 2021 -54.46 Mn